MAURICE FIEDEL: Open Payments
NPI 1265035257 · RIVERTON, UT. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$947 in 49 payments from 11 companies in 2025. Trend: 2023 $868 · 2024 $873 · 2025 $947
Food & beverage: $947
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 13 | $282 |
| Teva Pharmaceuticals USA, Inc. | 12 | $154 |
| Neurocrine BioSciences, Inc. | 5 | $112 |
| E.R. Squibb & Sons, L.L.C. | 5 | $81 |
| Alkermes, Inc. | 3 | $74 |
| Janssen Pharmaceuticals, Inc | 3 | $74 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $60 |
| Axsome Therapeutics, Inc. | 2 | $38 |
| Lundbeck LLC | 2 | $36 |
| Otsuka America Pharmaceutical, Inc. | 1 | $19 |
Products named: VRAYLAR, AUSTEDO XR, INGREZZA, COBENFY, TRINTELLIX, REXULTI, INVEGA SUSTENNA, ARISTADA.
Industry payments across UT — which companies pay providers there.
